Global Dental Equipment Market Anticipated to Generate a Revenue of $15,471.7 Million and Rise at a CAGR of 6.5% throughout the Analysis Period from 2022-2031 [250-Pages] | Issued by Research Dive
January 17, 2023 09:01 ET
|
Research Dive
New York, USA, Jan. 17, 2023 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global dental equipment market is envisioned to garner a revenue of $15,471.7 million and grow...
Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021
July 28, 2021 16:05 ET
|
Histogen Inc
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
February 16, 2021 08:00 ET
|
Histogen Inc
HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Planning Underway for Next Clinical Study in U.S. SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:...
Histogen to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
January 06, 2021 08:00 ET
|
Histogen Inc
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Announces Closing of $14.0 Million Upsized Public Offering
January 05, 2021 16:05 ET
|
Histogen Inc
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...
Histogen Announces Pricing of $14.0 Million Upsized Public Offering
December 30, 2020 22:25 ET
|
Histogen Inc
SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...
Histogen Announces Filing an Investigational New Drug Application for HST-003
December 17, 2020 08:00 ET
|
Histogen Inc
Phase 1/2 Trial Initiation for Knee Cartilage Regeneration Anticipated in First Quarter 2021 $2M Grant Awarded by the Department of Defense in September 2020 to Support Clinical Development SAN...
Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
December 01, 2020 08:00 ET
|
Histogen Inc
HST-001 Demonstrated Separation from Placebo at Week 18 Primary Efficacy Endpoint Assessment HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Week 26 Final Study Results...
Histogen Announces Closing of $4.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
November 16, 2020 16:05 ET
|
Histogen Inc
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...
Histogen Announces $4.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
November 12, 2020 08:00 ET
|
Histogen Inc
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...